KLK2 and prostate carcinoma: The introduction of KLK2 × CD3 increased interactions between prostate cancer target cells (VCaP) and T cells from healthy male donors 1.5× and 2× compared with a null × CD3 control construct or with coincubation with no bispecific antibody, respectively (Supplementary Fig. S4A).